In his first speech to Congress, President Joe Biden echoed the call for lower prescription drug costs that we have been hearing for many years. Democrats have been eying government negotiated drug ...

Off-patent medicines provide people with access to high-quality essential treatment options that can be significantly less expensive than branded on-patent medicines. Off-patent therapies — generics ...

Amneal has submitted ANDAs to the Food and Drug Administration for the following three complex generics: Injectable propofol emulsion, the generic version of Diprivan, is an I.V. general anesthetic ...

More than just inexpensive substitutes, generic drugs offer a glimpse into certain issues that pharmaceutical companies are facing now. While consumers depend on generics as a low-cost alternative to ...

MIRAMAR, Fla., Feb. 12, 2026 /PRNewswire/ -- DifGen Pharmaceuticals, a leading US based generic pharmaceutical company, today announced that it has received approval from the U.S. Food and Drug ...

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”) today announced the approval and launch of fluorometholone ophthalmic suspension. The ...

Even as Novartis puts its generics outfit under a magnifying glass, Sandoz continues to grow. Angling to beef up in respiratory medicine and complex generics, Sandoz has acquired British medical and ...

Lupin plans its next phase of global growth in the US with a focus on complex generics, biosimilars and innovation, as the ...

Teva is the leading generic drug manufacturer in the world. By our estimate, roughly 70% of Teva’s total sales are derived from generics and off-patent branded drugs and it continues to suffer low- to ...

Generics may still account for the majority of U.S. prescriptions, but they no longer guarantee attractive economics. Aggressive competition and steady price declines have eroded profitability in ...

Viatris Inc. VTRS delivered adjusted earnings of 78 cents per share in the third quarter of 2023, down from 87 cents in the year-ago quarter but beating the Zacks Consensus Estimate of 74 cents per ...